Overview

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Status:
Active, not recruiting

Trial end date:
2021-10-01

Target enrollment:

Participant gender:

Summary

This trial studies the best dose and side effects of utomilumab (4-1BB agonist monoclonal antibody PF-05082566) with trastuzumab emtansine or trastuzumab in treating patients with HER2-positive breast cancer that has spread to other places in the body. Monoclonal antibodies, such as utomilumab, trastuzumab emtansine, and trastuzumab may interfere with the ability of tumor cells to grow and spread.

Phase:

Phase 1

Details

Lead Sponsor:

George W. Sledge Jr.

Collaborator:

National Cancer Institute (NCI)

Treatments:

Ado-Trastuzumab Emtansine
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoconjugates
Immunoglobulin G
Immunoglobulins
Maytansine
Trastuzumab